Second, there is some evidence, but not entirely clear-cut, that old-school typical antipsychotics like Haloperidol causes more shrinking of gray matter, but the case is in complete reverse when it comes to atypicals (pretty much EVERY first-line drug used to treat the disorder these days) - they actually CAUSE NEUROGENESIS! : D
In this study Olanzapine (atypical antipsychotic), just like Haloperidol, caused a significant reduction in brain volume that affects both gray and white matter:
http://www.nature.co...l/1300710a.html
There's a few problems with your reference here - firstly, it's from 2005, and it's only one study. The review I posted was from 2015 and included a lot of other studies.
And then there's this study, from 2004, which shows that Olanzapine reverses some of the potential damage from Haloperidol.
Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol.
http://www.ncbi.nlm....pubmed/14746882
Now, your study was on macaque Apes, while mine is on rats - so I suppose one can chalk it up to some kind of metabolic difference between the two species, but the 2015 review included humans as well, showing neuroptrophic effects.
As I understand it, this is a long-running debate, regarding what the effects are...
But, to me, the newer review is proof that the atypicals increase neurogenesis.
I found another review which looked specifically at this, and it appeared as if the reductions were much smaller in Olanzapine-use than in Haloperidol-use. One possibility is of course that it's dose-dependant - depending on high or low dose, you get different results, with Olanzapine in particular.
For instance, good ol' Fluoxetine poops out as well
https://molecularbra.../1756-6606-4-10
I suppose a final possibility is that it's the more modulating Atypicals which have the positive effect - e.g Aripiprazole and Brexpiprazole.
Otherwise, how do you explain the fact that Brexpiprazole works on depression, according to this study? (which got it approved by the FDA for MDD treatment)
Lundbeck Reports Positive Phase III Results Of Depression Treatment Brexpiprazole
http://www.clinicall...xpiprazole-0001
Over 90% of patients completed the randomized phase of the trial
That amount of patients completing the trial in perticular, is rather encouraging, wouldn't you say? As far as I understand it, that's actually way, WAY above average when it comes to AD-trials, so either these are the most patient and abiding patients ever, or it's damn good stuff.
But you have a point - Brex ain't Abilify or Olanzapine, it may be something all-new.